Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: | Hematology | Oncology | Pediatrics/Neonatology
Search Medical Condition
Leukemia (Pediatric) Clinical Trials
A listing of Leukemia (Pediatric) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found (262) clinical trials
AALL0631: A Phase III Study of Risk Directed Therapy for Infants with Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; IND #76431; NSC# 617807)
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00557193?term=AALL0631&rank=1
AALL0932: Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01190930?term=AALL0932&rank=1
ACCL0993: A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infection in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01307579?term=Children%27s+Oncology+Group&cond=Prevent+Invasive+Fungal+Infection+in+Children+Undergoing+Chemotherapy+for+Acute+Myeloid+Leukemia+%28AML%29&rank=1
AALL0434: Combination Chemotherapy in Treating Young Patients with Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT00408005?term=AALL0434&rank=2
AALL08B1: Risk-Based Classification System of Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01142427?term=AALL08B1&rank=1
AALL1131, A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789) in the Very High Risk Stratum.
For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01406756?term=AALL1131&rank=1
MSC and HSC Coinfusion in Mismatched Minitransplants
The present project aims at evaluating the capacity of MSC to improve one-year overall survival of patients transplanted with HLA-mismatched PBSC from related or unrelated donors after non-myeloablative conditioning. Co-infusion of MSC has been shown to facilitate engraftment of hematopoietic stem cell (HSC) in an immunodeficient mouse model. In addition, ...
Low-Dose Daunorubicin in Relapsed/Refractory Acute Leukemia
Disease relapse remains the primary challenge in the treatment of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL). There is no standard of care treatment option for relapsed acute leukemia, and investigational therapies are recommended. Clinically targeting the leukemia stem cell (LSC) remains an unmet need in both AML ...
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
The purpose of this study is to test the safety of giving the patient special cells from a donor called "Modified T-cells". The goal is to find a safe dose of modified T-cells for patients with relapsed B cell leukemia or lymphoma after a blood SCT. The investigators also want ...
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Study Drug Administration: Every study cycle will be 6 weeks. You may receive up to 4 cycles of blinatumomab. Each cycle will start around 3, 6, 9, and 12 months after your stem cell transplant. In each cycle, you will receive blinatumomab as a continuous infusion by vein for 4 ...
